Skip to content
MarketNewsAPI
Live news Screener Coverage Pricing Docs REST API WebSocket API MCP server Company Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
PONIF$0.12-0.00(-3.70%)Silver Pony Announces Closing of Up-Sized $1,600,015 Strategic Unit Offering[6:15:00 PM ET]ELME$0.07-1.70(-96.19%)Elme Communities Announces Suspended NYSE Trading; Anticipates Trading Will Begin OTC Effective October 26, 2026[5:47:00 PM ET]HHH$72.57+3.08(+4.43%)Howard Hughes Holdings Set to Join S&P SmallCap 600 Howard Hughes Holdings Inc. (NYSE: HHH) will replace Arcosa Inc. (NYSE: ACA) in the S&P SmallCap 600 effective prior to the opening of trading on...[5:45:00 PM ET]ALGRF$0.400.00(0.00%)Algo Grande Commissions Independent NI 43-101 Update to Capture First Year of Progress at Adelita[5:30:00 PM ET]ZEFIF$0.45+0.02(+3.56%)Zefiro Announces Closing of Non-Brokered Private Placement for Gross Proceeds of Approximately C$5.0 Million[5:29:00 PM ET]BLK$1,118.50-18.79(-1.65%)BlackRock® Canada Announces the Termination of iShares Convertible Bond Index ETF[5:23:34 PM ET]ITFS$1.43-0.02(-1.10%)Itafos Announces Release Date for Q3 2026 Results and Business Update Webcast[5:15:00 PM ET]FAGI$0.01-0.00(-13.33%)Full Alliance Group, Inc (OTC:FAGI) YAHBEE Highlights Community-Commerce Model for Agentic Commerce Era[5:15:00 PM ET]TGT$152.76-5.35(-3.38%)Vital Farms Introduces a Higher Standard for Free-Range Eggs Through Limited Pilot at Select Target Retail Stores[5:05:00 PM ET]NU$15.23+0.50(+3.39%)Notice to Market: Nu Holdings Ltd.[5:03:00 PM ET]POR$44.55-0.35(-0.78%)Portland General Electric Declares Dividend[5:00:00 PM ET]ANTX$3.55-0.09(-2.47%)AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)[5:00:00 PM ET]

TAK · NYSE

Takeda Pharmaceutical Company Limited

$20.24 -0.12 (-0.61%)

Company overview

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NYSE
Market cap
$64.4B
Employees
49,281
Headquarters
Tokyo
Website
takeda.com
CEO
Christophe Weber
Listed
January 5, 2010
P/E
0.33
Dividend yield
3.40%

Company financials

Revenue
$4.5T
Gross profit
$2.7T
Operating income
$495B
EBITDA
$1.4T
Net income
$193B
EPS
$61.44
Total assets
$15.5T
Total debt
$4.9T
Gross margin
58.47%
Net margin
4.25%
Earnings yield
303.56%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

14.6216.1217.6219.1120.61
TAK 1D NYSE O20.18H20.39L20.08C20.36+0.43 (+2.16%)Vol3.46M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
TAK Press release Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study Business Wire
TAK Press release First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication Business Wire
TAK Stock news Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1 GuruFocus
TAK Press release Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1 Business Wire
TAK Stock news Takeda Remains A Buy, Boosted By Recent Narcolepsy Drug Approval And Robust Pipeline Seeking Alpha
TAK Stock news Takeda Pharmaceutical (NYSE:TAK) vs. RYTHM (NASDAQ:RYM) Financial Survey Defense World
TAK Stock news Takeda Pharmaceutical (NYSE:TAK) versus Teva Pharmaceutical Industries (NYSE:TEVA) Financial Contrast Defense World
TAK Stock news Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
TAK Press release U.S. FDA Accepts New Drug Application Under Priority Review for Takeda's Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations Business Wire
TAK Press release Trialbee to Present with Takeda, Showcase AI for Clinical Sites, and Unveil AI-Powered Patient Screening at DPHARM 2026 Business Wire
TAK Stock news Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now? Zacks Investment Research
TAK Stock news US FDA approves Takeda, Protagonist's drug for rare blood cancer Reuters
TAK Press release ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 Business Wire
TAK Stock news Wall Street Analysts Think Takeda Pharmaceutical Co. (TAK) Could Surge 26.41%: Read This Before Placing a Bet Zacks Investment Research
TAK Stock news Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock? Zacks Investment Research
TAK Stock news Takeda's Pipeline Looks Encouraging, But Generic Erosion Is A Near-Term Concern Seeking Alpha
TAK Stock news Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval Benzinga
TAK Press release U.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 Business Wire
TAK Stock news US FDA approves Takeda's sleep disorder pill Reuters
TAK Stock news Takeda Pharmaceutical (TAK) to Announce Quarterly Earnings on Thursday Defense World
See more
FAQ

Questions about Takeda Pharmaceutical Company Limited

What does Takeda Pharmaceutical Company Limited do?
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands.
What is TAK's market cap?
Takeda Pharmaceutical Company Limited (TAK) is a listed stock with a live quote. The latest market cap on this page is $64.4B.
Where is Takeda Pharmaceutical Company Limited headquartered?
Takeda Pharmaceutical Company Limited is headquartered in Tokyo.
How do I get TAK news from the API?
Call GET /v1/news?tickers=TAK. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does TAK news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for TAK, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the TAK price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included. If you don't subscribe, the account stays on Free.

Start 7-day free trial Read the docs